Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells

D. Arango, A. J. Wilson, Q. Shi, G. A. Corner, M. J. Arañes, C. Nicholas, M. Lesser, J. M. Mariadason, Leonard H. Augenlicht

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the treatment of colorectal cancer. In this study, we investigate the molecular mechanisms of action of oxaliplatin to identify means of predicting response to this agent. Exposure of colon cancer cells to oxaliplatin resulted in G2/M arrest and apoptosis, Immunofluorescent staining demonstrated that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c release into the cytosol. Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association. Targeted inactivation of Bax or p53 in HCT116 cells resulted in significantly increased resistance to oxaliplatin. However, the mutational status of p53 was unable to predict response to oxaliplatin in a panel of 30 different colorectal cancer cell lines, In contrast, the expression profile of these 30 cell lines, assessed using a 9216-sequence cDNA microarray, successfully predicted the apoptotic response to oxaliplatin. A leave-one-out cross-validation approach was used to demonstrate a significant correlation between experimentally observed and expression profile predicted apoptosis in response to clinically achievable doses of oxaliplatin (R = 0.53; P = 0.002). In addition, these microarray experiments identified several genes involved in control of apoptosis and DNA damage repair that were significantly correlated with response to oxaliplatin.

Original languageEnglish (US)
Pages (from-to)1931-1946
Number of pages16
JournalBritish Journal of Cancer
Volume91
Issue number11
DOIs
StatePublished - Nov 29 2004

Fingerprint

oxaliplatin
Colorectal Neoplasms
Apoptosis
Platinum Compounds
HCT116 Cells

Keywords

  • Apoptosis
  • Bax
  • Colorectal cancer microarray
  • Oxaliplatin
  • P53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. / Arango, D.; Wilson, A. J.; Shi, Q.; Corner, G. A.; Arañes, M. J.; Nicholas, C.; Lesser, M.; Mariadason, J. M.; Augenlicht, Leonard H.

In: British Journal of Cancer, Vol. 91, No. 11, 29.11.2004, p. 1931-1946.

Research output: Contribution to journalArticle

Arango, D, Wilson, AJ, Shi, Q, Corner, GA, Arañes, MJ, Nicholas, C, Lesser, M, Mariadason, JM & Augenlicht, LH 2004, 'Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells', British Journal of Cancer, vol. 91, no. 11, pp. 1931-1946. https://doi.org/10.1038/sj.bjc.6602215
Arango, D. ; Wilson, A. J. ; Shi, Q. ; Corner, G. A. ; Arañes, M. J. ; Nicholas, C. ; Lesser, M. ; Mariadason, J. M. ; Augenlicht, Leonard H. / Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. In: British Journal of Cancer. 2004 ; Vol. 91, No. 11. pp. 1931-1946.
@article{4b41caae71ff48af82d8a6cc796a755b,
title = "Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells",
abstract = "The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the treatment of colorectal cancer. In this study, we investigate the molecular mechanisms of action of oxaliplatin to identify means of predicting response to this agent. Exposure of colon cancer cells to oxaliplatin resulted in G2/M arrest and apoptosis, Immunofluorescent staining demonstrated that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c release into the cytosol. Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association. Targeted inactivation of Bax or p53 in HCT116 cells resulted in significantly increased resistance to oxaliplatin. However, the mutational status of p53 was unable to predict response to oxaliplatin in a panel of 30 different colorectal cancer cell lines, In contrast, the expression profile of these 30 cell lines, assessed using a 9216-sequence cDNA microarray, successfully predicted the apoptotic response to oxaliplatin. A leave-one-out cross-validation approach was used to demonstrate a significant correlation between experimentally observed and expression profile predicted apoptosis in response to clinically achievable doses of oxaliplatin (R = 0.53; P = 0.002). In addition, these microarray experiments identified several genes involved in control of apoptosis and DNA damage repair that were significantly correlated with response to oxaliplatin.",
keywords = "Apoptosis, Bax, Colorectal cancer microarray, Oxaliplatin, P53",
author = "D. Arango and Wilson, {A. J.} and Q. Shi and Corner, {G. A.} and Ara{\~n}es, {M. J.} and C. Nicholas and M. Lesser and Mariadason, {J. M.} and Augenlicht, {Leonard H.}",
year = "2004",
month = "11",
day = "29",
doi = "10.1038/sj.bjc.6602215",
language = "English (US)",
volume = "91",
pages = "1931--1946",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells

AU - Arango, D.

AU - Wilson, A. J.

AU - Shi, Q.

AU - Corner, G. A.

AU - Arañes, M. J.

AU - Nicholas, C.

AU - Lesser, M.

AU - Mariadason, J. M.

AU - Augenlicht, Leonard H.

PY - 2004/11/29

Y1 - 2004/11/29

N2 - The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the treatment of colorectal cancer. In this study, we investigate the molecular mechanisms of action of oxaliplatin to identify means of predicting response to this agent. Exposure of colon cancer cells to oxaliplatin resulted in G2/M arrest and apoptosis, Immunofluorescent staining demonstrated that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c release into the cytosol. Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association. Targeted inactivation of Bax or p53 in HCT116 cells resulted in significantly increased resistance to oxaliplatin. However, the mutational status of p53 was unable to predict response to oxaliplatin in a panel of 30 different colorectal cancer cell lines, In contrast, the expression profile of these 30 cell lines, assessed using a 9216-sequence cDNA microarray, successfully predicted the apoptotic response to oxaliplatin. A leave-one-out cross-validation approach was used to demonstrate a significant correlation between experimentally observed and expression profile predicted apoptosis in response to clinically achievable doses of oxaliplatin (R = 0.53; P = 0.002). In addition, these microarray experiments identified several genes involved in control of apoptosis and DNA damage repair that were significantly correlated with response to oxaliplatin.

AB - The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the treatment of colorectal cancer. In this study, we investigate the molecular mechanisms of action of oxaliplatin to identify means of predicting response to this agent. Exposure of colon cancer cells to oxaliplatin resulted in G2/M arrest and apoptosis, Immunofluorescent staining demonstrated that the apoptotic cascade initiated by oxaliplatin is characterised by translocation of Bax to the mitochondria and cytochrome c release into the cytosol. Oxaliplatin treatment resulted in caspase 3 activation and oxaliplatin-induced apoptosis was abrogated by inhibition of caspase activity with z-VAD-fmk, but was independent of Fas/FasL association. Targeted inactivation of Bax or p53 in HCT116 cells resulted in significantly increased resistance to oxaliplatin. However, the mutational status of p53 was unable to predict response to oxaliplatin in a panel of 30 different colorectal cancer cell lines, In contrast, the expression profile of these 30 cell lines, assessed using a 9216-sequence cDNA microarray, successfully predicted the apoptotic response to oxaliplatin. A leave-one-out cross-validation approach was used to demonstrate a significant correlation between experimentally observed and expression profile predicted apoptosis in response to clinically achievable doses of oxaliplatin (R = 0.53; P = 0.002). In addition, these microarray experiments identified several genes involved in control of apoptosis and DNA damage repair that were significantly correlated with response to oxaliplatin.

KW - Apoptosis

KW - Bax

KW - Colorectal cancer microarray

KW - Oxaliplatin

KW - P53

UR - http://www.scopus.com/inward/record.url?scp=11244303546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244303546&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602215

DO - 10.1038/sj.bjc.6602215

M3 - Article

C2 - 15545975

AN - SCOPUS:11244303546

VL - 91

SP - 1931

EP - 1946

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 11

ER -